In a recent interview, Northwestern’s Dr. Mary McDermott discussed key findings from her team’s randomized clinical trial investigating whether NAD+ booster Nicotinamide Riboside “NR” (FAQs) (Anecdotes) can enhance walking performance in patients with peripheral artery disease (PAD). The results (using 1000 mg NR) showed that NR significantly improved six-minute walking distance and treadmill walking time in PAD patients. A transcript and video of Dr. McDermott’s interview below:
Month: November 2023
While we await data from clinical trials on the efficacy of NAD+ boosters like Nicotinamide Riboside “NR” (FAQs) (Anecdotes) and Nicotinamide Mononucleotide “NMN” (FAQs and Anecdotes), we’re always on the lookout for comments from experts in the field to hear their current thinking. Earlier this week at an investor conference, Chromadex (NR seller) management had the following to say about NR for Parkinson’s patients (transcript and video below):
Once you’ve decided to supplement with NAD+ booster Nicotinamide Riboside “NR” (FAQs) (Anecdotes), you might wonder what dose to take. If that’s the case, you might find this post helpful. And what about the new 1000mg version from Chromadex? Here’s how management explained it on last week’s earnings call:
While consumers claim to have experienced a variety of life-changing benefits from taking NAD+ boosting supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes), NAD+ expert Charles Brenner (FAQs) says he takes it for the following reasons:
Yesterday, we heard Stanford neuroscientist Dr. Andrew Huberman describe experiencing “sustained mental and physical energy” from taking NAD+ supplements Nicotinamide Riboside “NR” (FAQs) (Anecdotes) and Nicotinamide Mononucleotide “NMN” (FAQs and Anecdotes). What about his experience with NAD+ IVs (FAQs)? Here’s what he said (transcript and video below):
While admittedly not an NAD+ expert, Stanford neuroscientist Dr. Andrew Huberman is very interested in the NAD+ space. He currently takes NR (FAQs) (Anecdotes) and NMN (FAQs and Anecdotes). Here’s what he said on an AMA yesterday (key points in bold, summary at the end):